摘要
目的探讨联合检测肾母细胞瘤基因1(WT1)和融合基因在急性髓细胞性白血病(AML)微小残留病(MRD)中的应用价值。方法收集2018年1月至2020年12月于该院确诊并完成RUNX1-RUNX1T1、早幼粒细胞白血病蛋白(PML)/视黄酸受体(RAR)α和WT1基因检测的伴重现性遗传学异常的AML患者。检测RUNX1-RUNX1T1、PML/RARα和WT1转录本水平,将RUNX1-RUNX1T1、PML/RARα融合基因转录本水平为0%看作融合基因阴性组,将RUNX1-RUNX1T1或PML/RARα融合基因转录本水平均不为0%看作融合基因阳性组。结果融合基因阴性组患者WT1转录本水平为0.096%(0.007%,1.990%),融合基因阳性组患者WT1转录本水平为1.420%(0.100%,60.340%),融合基因阴性组患者WT1转录本水平低于融合基因阳性组患者(P<0.05)。融合基因高表达组(融合基因转录本水平≥1%)患者融合基因转录本水平高于WT1转录本水平(P<0.05),融合基因低表达组(融合基因转录本水平<1%)患者WT1转录本水平高于融合基因转录本水平(P<0.05)。结论可联合检测融合基因和WT1,以此提高MRD的检测灵敏度。
Objective To investigate the application value of combined detection of wilms tumor gene 1(WT1)and fusion gene in acute myeloid leukemia(AML)minimal residual disease(MRD).Methods The AML patients diagnosed with RUNX1-RUNX1T1 or promyelocytic leukemia protein(PML)/retinoic acid receptor(RAR)αand WT1 gene detection in our hospital from January 2018 to December 2020 were collected.The transcript levels of RUNX1-RUNX1T1,PML/RARαand WT1 were detected,and the fusion gene negative group was defined as the RUNX1-RUNX1T1 or PML/RARαfusion gene transcript level of 0%,the fusion gene positive group was defined as RUNX1-RUNX1T1 or PML/RARαfusion gene transcript level was not 0%.Results The WT1 transcript level of the fusion gene negative group was 0.096%(0.007%,1.990%),and the fusion gene positive group was 1.420%(0.100%,60.340%),the level of WT1 transcript in fusion gene negative group was lower than that in fusion gene positive group(P<0.05).The fusion gene transcript level of patients in the fusion gene high expression group(fusion gene transcript level≥1%)was higher than that of WT1 transcript(P<0.05),the fusion gene low expression group(fusion gene transcript level<1%),the WT1 transcript level was higher than the fusion gene transcript level(P<0.05).Conclusion The fusion gene and WT1 can be detected together to improve the detection sensitivity of MRD.
作者
李乾鹏
曹荣旋
张俊英
孙艳花
王宝宏
冉学红
LI Qianpeng;CAO Rongxuan;ZHANG Junying;SUN Yanhua;WANG Baohong;RAN Xuehong(Department of Hematology,Weifang People′s Hospital,Weifang,Shandong 261000,China)
出处
《国际检验医学杂志》
CAS
2022年第3期313-316,321,共5页
International Journal of Laboratory Medicine
基金
山东省医药卫生科技发展计划项目(2018WS077、2017WS415)。
